Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis

Abstract

This study suggests that in active multiple sclerosis during treatment with injectable disease-modifying therapies, switching to natalizumab is more effective than switching to fingolimod in reducing relapse rate and short-term disability burden.